Individualized strategies to target specific mechanisms of disease in malignant melanoma patients displaying unique mutational signatures by Curiel-Olmo, Soraya et al.
Oncotarget25452www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 6, No. 28
Individualized strategies to target specific mechanisms of 
disease in malignant melanoma patients displaying unique 
mutational signatures
Soraya Curiel-Olmo1,*, Almudena García-Castaño2,*, Rebeca Vidal3,4,8, 
Helena Pisonero1, Ignacio Varela4, Alicia León-Castillo1,5, Eugenio Trillo6, 
Carmen González-Vela1,5, Nuria García-Diaz1, Carmen Almaraz1, Thaidy Moreno4, 
Laura Cereceda1, Rebeca Madureira1, Nerea Martinez1, Pablo Ortiz-Romero7, 
Elsa Valdizán3,4, Miguel Piris1,5,#, José Vaqué1,4,#
1Cancer Genomics Group, IDIVAL, Instituto de Investigación Marqués de Valdecilla, Santander, Spain
2Oncology Service, Hospital Universitario Marqués de Valdecilla, Santander, Spain
3 Department of Pharmacology, University of Cantabria (UC), Santander, Spain, and Centro de Investigación Biomédica en 
Red de Salud Mental (CIBERSAM), ISCIII, Madrid, Spain
4 Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), CSIC, Universidad de Cantabria, Departamento de Biología 
Molecular, Universidad de Cantabria, Santander, Spain
5Pathology Service, Hospital Universitario Marqués de Valdecilla, Santander, Spain
6Plastic Surgery Service Hospital Universitario Marqués de Valdecilla, Santander, Spain
7Dermatology Service, Instituto I+12, Hospital Universitario 12 de Octubre, Madrid, Spain
8Department of Pharmacology, Medicine School, Complutense University, Madrid, Spain
*These authors have contributed equally to this work
#Senior author
Correspondence to:
José Vaqué, e-mail: vaquej@unican.es
Keywords: Targeted therapy, melanoma, BRAF, MAPK, somatic mutations
Received: March 25, 2015  Accepted: July 13, 2015  Published: July 25, 2015
ABSTRACT
Targeted treatment of advanced melanoma could benefit from the precise 
molecular characterization of melanoma samples. Using a melanoma-specific 
selection of 217 genes, we performed targeted deep sequencing of a series of 
biopsies, from advanced melanoma cases, with a Breslow index of ≥4 mm, and/or 
with a loco-regional infiltration in lymph nodes or presenting distant metastasis, as 
well of a collection of human cell lines. This approach detected 3–4 mutations per 
case, constituting unique mutational signatures associated with specific inhibitor 
sensitivity. Functionally, case-specific combinations of inhibitors that simultaneously 
targeted MAPK-dependent and MAPK-independent mechanisms were most effective 
at inhibiting melanoma growth, against each specific mutational background. These 
observations were challenged by characterizing a freshly resected biopsy from a 
metastatic lesion located in the skin and soft tissue and by testing its associated 
therapy ex vivo and in vivo using melanocytes and patient-derived xenografted mice, 
respectively.
The results show that upon mutational characterization of advanced 
melanoma patients, specific mutational profiles can be used for selecting drugs 
that simultaneously target several deregulated genes/pathways involved in tumor 
generation or progression.
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INTRODUCTION
Melanoma is a form of cancer whose incidence is 
rising each year in the developed world, and is second to 
leukemia in terms of loss of years of potential life from 
cancers [1]. Despite recent improvements in mortality 
rates, current deaths from melanoma are estimated to 
comprise 85% of all cancers affecting the skin. This 
is corroborated by the poor survival associated with 
melanoma when diagnosed at an advanced stage [2]. 
Therefore, the development of effective therapies is a 
major challenge in this field.
Molecular diagnostics of cancer have proved 
that targeted therapies can be effective in many cancer 
settings, as measured by the recent improvement in 
cancer survival statistics (World Cancer Statistics 
2008; ICD-10 C18–21). The use of EGFR inhibitors 
in lung cancer [3, 4] and Imatinib in chronic myeloid 
leukemia (CML) patients [5] are two relevant examples. 
Targeted therapies in melanoma are mostly directed 
towards inhibiting MAPK-ERK1/2 signaling (MAPK 
hereafter), [6]. Mutational analyses have recently enabled 
the detection of up to 50% of malignant melanomas 
carrying an activating mutation in BRAF [7], and these 
can now be treated with specific B-RAF inhibitors [8]. 
In the clinic, this targeted approach, even when used in 
combination with MEK inhibitors, is of limited benefit to 
patient survival and, after a period, the cancer reappears 
aggressively [9–11].
From a molecular perspective, data from Next 
Generation Sequencing (NGS) show that more mutated 
genes than initially expected participate in tumorigenesis, 
including that of melanoma [12–14]. This involves a 
dynamic process of subclonal competition that eventually 
dictates multifactorial clinical resistance to B-RAF 
inhibitors, which is dependent on reactivation of MAPK 
signaling or other proliferative and/or pro-survival 
pathways [15–17].
Taking advantage of available melanoma 
NGS data, we characterized biopsies from advanced 
melanoma patients and cell lines by studying the 
presence of somatic mutations in a selected group of 
genes. We thereby detected unique signatures of mutated 
genes that are potentially associated with specific 
inhibitors, and explored the effects of case-specific 
combinations of the latter ex vivo and in vivo. Guided 
by individual mutational profiles, tailored combinations 
of inhibitors simultaneously targeting MAPK-
dependent and MAPK-independent signaling were 
very efficient at inhibiting aberrant melanoma growth 
assessed in multiple cell lines, and xenografted tumors 
and biopsies grown in mice. Thus, specific mutational 
signatures could guide the design of personalized 
therapies based on the use of specific combinations 
of drugs that target case-specific pathogenic signaling 
mechanisms.
RESULTS
A targeted approach to characterizing the 
mutational status of lesions of advanced 
melanoma patients
To better understand the molecular character 
of specific melanoma lesions, we set up a targeted 
mutational study followed by functional analyses 
(described in Supplementary Figure 1). The genomic 
design of this study focused on the coding regions of 
a specific group of 217 genes that had previously been 
shown to be mutated in melanoma and selected mainly 
on the basis of their relevance in melanoma and their 
association with inhibitors of potential clinical use (see 
Materials and Methods for further explanation). To test 
this approach our selection of genes was compared in 
silico with the whole genome/exome sequencing (WGS/
WES respectively) data already available for 11 advanced 
melanoma cell lines and 158 human melanomas (see 
Materials and Methods, [13, 14, 18, 19]). This comparison 
revealed an average of 3.74 mutated genes that can 
participate in multiple targetable signaling pathways, 
including PLC, MAPK, RTKs (receptors with tyrosine 
kinase activity), PI3K-mTOR and JAK-STAT (Figure 1 
and Supplementary Table I). These results prompted us to 
study advanced melanoma cases (Breslow index ≥4 mm or 
metastasis) in 18 clinically characterized patients (clinical 
characteristics summarized in Supplementary Table II) 
using a targeted primary ultrasequencing approach, 
followed by secondary validation analysis (see Materials 
and Methods for further details). By these methods, an 
average of 3.4 mutated genes were identified in 11 of the 
18 patients, enabled the detection of lesion-specific genes 
such as BRAF, RAC1, KRAS, HGF and MAPK7, amongst 
others. Interestingly, there was a wide range of mutation 
frequencies and combinations, which perhaps reflects the 
rich and heterogeneous microclonal composition expected 
in melanoma tumors (400X average depth/mutation; 
Table I) [20]. Furthermore, actionable mutations such as 
BRAFV600E that can guide targeted therapy (using B-RAF 
inhibitors) were detected in the same melanoma alongside 
other mutated genes that may also guide therapy (Table I). 
It is significant that mutations in four patients could not 
be validated due to limitations of the tissue sample (see 
Materials and Methods), and that no mutations were 
identified in three other patients. Thus, this targeted 
approach could be adopted to identify genomic alterations 
affecting one or several genes. These may be explored as 
potential targets for therapy in specific cases of melanoma.
Effects of specific targeted therapy guided by 
mutational signature
To explore how to use mutational data to 
design targeted therapies based on specific mutational 
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characterizations, the functional effects of specific 
combination therapies were studied in advanced melanoma 
cell lines with known mutational profiles (Supplementary 
Table III). Taking A375 advanced melanoma cells as an 
example, we detected and validated mutations in BRAF, 
FGFR2 and mTOR that could reasonably be expected 
to associate with Vemurafenib (BRAFi (V), hereafter), 
Vargatef (FGFR2i (Va)) and Everolimus (mTORi (E)). 
Exponentially growing A375 cells were incubated with 
increasing concentrations of each inhibitor. This caused 
a concentration-dependent reduction in cell proliferation 
from which the IC50 of each inhibitor was calculated 
(Figure 2A and Supplementary Table III). These 
concentrations were used for subsequent experiments. 
Next, the mechanistic effects of treatment with each 
inhibitor (using IC50 values in each case) were analyzed 
in A375 cells that had been serum-starved to provoke the 
inhibition of the intended mutation-associated downstream 
signaling. These were assessed by western blot using 
P-ERK1/2, P-p38 and P-S6 antibodies (Figure 2B).
To discover more about the biological effects of 
multiple combinations of these inhibitors on proliferation, 
A375 cells were incubated with IC50 concentrations of 
BRAFi, FGFR2i and mTORi in single, double or triple 
combinations (blue, green and red lines, respectively, 
in Figure 2C). The combinatorial treatments were more 
effective at reducing melanoma cell growth than the 
monotherapies. The triple combination was the most 
efficient, and had no non-specific cytotoxic effects 
(Figure 2C and 2E). These results were confirmed 
using DNA synthesis as an alternative read-out 
(Figure 2D and 2E). Thus, under these conditions, 
a combination of inhibitors guided by a specific 
mutational signature, simultaneously targeted multiple 
signaling mechanisms controlling the growth of A375 
cells. Analyzing the mechanistic effects of these drug 
combinations on their associated signaling pathways in 
this system, showed that treatment with BRAFi inhibited 
MAPK signaling. However, treatment of A375 cells with 
the inhibitors mTORi and FGFR2i, alone or in combination 
(E+Va), had no such effect (Figure 2F and 2G), despite 
being very effective at inhibiting cell proliferation 
and DNA synthesis (Figures 2C, and 2E). Thus, using 
genetically defined inhibitors in this system we can 
specifically target a combination of MAPK-dependent (V) 
and MAPK-independent (E+Va) signaling mechanisms 
that control the malignant growth of A375 melanoma 
cells. This observation was not confined to these cells and 
more examples of specific mutational signatures guiding 
effective combinatorial therapies comprising MAPK-
dependent and MAPK-independent mechanisms in other 
human advanced melanoma cell models are shown in 
Supplementary Figures 2, 3 and 5.
Increased effects of targeted therapy against an 
appropriate mutational background
As part of a heterogeneous network of aberrant 
intracellular signaling, multiple deregulated pathways 
can participate in the mechanistic control of melanoma 
growth (Figure 1). We examined whether a combination 
therapy designed for a specific mutational signature could 
Figure 1: In silico-targeted mutational profiling of advanced melanoma patients. A. Meta-analysis showing the average 
number of mutated genes per case with the potential to guide targeted therapy. Original mutational data from cell lines (red bar) were 
obtained from the Cancer Cell Line Encyclopedia website (see Material and Methods); mutational data from patients (grey bars) were 
obtained from Nilolaev [19], Hodis [18], Stark [14] and Berger [13]; Black bar, shows the average frequency of mutations amongst all data 
sets. B. Percentage of hits in A) involved in the indicated signaling pathway.
Oncotarget25455www.impactjournals.com/oncotarget
Table 1: Validated mutations found in advanced melanoma patients
Patient Chrom. Position Ref_base Mut_base Total_Cov Observed_Freq Gene_ID p.Annot
2 Chr4 126370467 G A 59 0.58 FAT4 p.E2766K
2 Chr2 141986902 C T 83 0.18 LRP1B p.E234K
4 Chr5 167881030 GGA - 464 0, 53 WWC1 p.V861 VE > V
4 Chr5 150923714 T C 724 0.39 FAT2 p.N2325S
4 Chr17 7578490 A C 884 0.08 TP53 p.V147G
5 Chr12 25380269 C G 177 0, 16 KRAS p.E63D
5 Chr1 9781272 G C 424 0, 07 PIK3CD p.G593R
6 Chr7 140453136 A T 39 0, 69 BRAF p.V600E
6 Chr3 3134041 T A 100 0, 3 IL5RA p.E287D
6 Chr19 15290897 C T 1200 0, 27 NOTCH3 p.G1105S
8 Chr7 6426892 C T 233 0, 67 RAC1 p.P29S
8 Chr7 81346551 G A 243 0, 61 HGF p.R468C
8 Chr7 140453136 AC CT 61 0, 54 BRAF p.V600R
8 Chr3 155311800 C T 145 0, 49 PLCH1 p.G104S
8 Chr18 51053024 CC TT 119 0, 48 DCC p.S1383F
8 Chr5 89910783 C T 60 0, 4 GPR98 p.R52C
8 Chr1 23233289 T G 76 0, 39 EPHB2 p.Y659D
8 Chr13 28886195 C T 190 0, 32 FLT1 p.E1143K
8 Chr18 50432552 C T 163 0, 37 DCC p.P184L
8 Chr2 170136083 C T 38 0, 29 LRP2 p.G455D
8 Chr11 46406865 G A 1048 0, 27 CHRM4 p.P415S
9 Chr7 31855742 C T 66 0, 24 PDE1C p.E597K
9 Chr7 140453135 CA TT 55 0, 11 BRAF p.V600E
12 Chr7 140453136 A T 142 0, 1 BRAF p.V600E
12 Chr6 32170007 C T 302 0, 06 NOTCH4 p.G1201R
13 Chr2 166905414 C T 321 0, 15 SCN1A p.G337E
13 Chr5 55247832 G A 362 0, 12 IL6ST p.L542F
16 Chr16 9858517 C T 450 0, 06 GRIN2A p.E962K
17 Chr7 140453136 A T 326 0, 44 BRAF p.V600E
17 Chr4 126239082 C T 1417 0, 27 FAT4 p.L506F
17 Chr17 19285669 C T 1646 0, 23 MAPK7 p.P546S
17 Chr18 50450115 C T 371 0, 2 DCC p.P246S
18 Chr10 96014751 C T 651 0, 13 PLCE1 p.P1167S
18 Chr2 21233091 G A 167 0, 08 APOB p.H2217Y
18 Chr13 29001438 C T 824 0, 08 FLT1 p.E432K
18 Chr7 151851165 CC TT 876 0, 08 KMT2C p.G4069N
18 ChrX 112035176 C T 420 0, 07 AMOT p.E195K
Patient: Patient number; Chrom: Chromosome number; Position: Genomic location of the mutation in the chromosome; 
Ref_base: normal nucleotide; Mut_base: mutated nucleotide; Total Cov: Number of reads analyzed at each position; 
Observed_Freq: Frequency of mutation; Gene_ID: Gene name; pAnnot: Aminoacid change.
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be more effective when used against a genetically 
appropriate background. A group of melanoma cell lines 
harboring unique mutational signatures (Supplementary 
Table III) was treated in parallel with the genetically 
defined inhibitors for A375 cells, BRAFi, FGFR2i 
and mTORi, alone or in combination. In general, each 
treatment was more effective in A375 cells than in the 
other melanoma cell lines, with the possible exception 
of mTORi used alone (Figure 3A). The triple drug 
combination treatment (V+E+Va) simultaneously 
targeting MAPK-dependent and MAPK-independent 
proliferation mechanisms produced greater inhibition of 
A375 cell growth than the others (Figure 3A and 3B). 
Likewise, other specific treatments based on the 
combination of genetically defined inhibitors in other 
melanoma cell lines showed a stronger effect than that 
of A375 cells (Supplementary Figure 4A and 4B). More 
examples of specific mutational signatures guiding 
more effective combination therapies when used against 
an appropriate mutational background are shown in 
Figure 5E and Supplementary Figure 5C. In summary, 
based on specific mutational signatures, a specific 
treatment consisting of a combination of genetically 
defined inhibitors may have stronger anti-melanoma 
activity when used against an appropriate genomic 
background.
In vivo effects of a targeted therapy that 
combines MAPK-ERK-dependent and MAPK-
ERK-independent mechanisms of inhibition
To study the in vivo effects of targeted therapy 
oriented by a specific mutational profile, xenografted 
tumors from A375 melanoma cells were generated in 
BALB/C mice (nu−/−/nu−/−). Once grown to a volume 
of approximately 100 mm3, tumors were assigned 
to four comparable groups and treated daily with 
vehicle, a MAPK-dependent inhibitor (BRAFi), 
a MAPK-independent combination of inhibitors 
(FGFR2i+ mTORi), or a triple combination of the latter 
(BRAFi+FGFR2i+mTORi). As shown in Figure 4A 
and 4B, both treatments used independently reduced 
tumor growth to a similar extent. However, the triple 
combination (V+Va+E) proved most effective at 
reducing melanoma growth in this system. Once the 
experiment was finished, the remaining growth potential 
of these tumors was characterized by studying Ki67 
and the mitotic index in tumor sections. As might be 
expected, a marked decrease in both proliferation 
markers in those tumors treated with the combination 
of MAPK-dependent and MAPK-independent inhibitors 
(Figure 4C-4G) was observed, thereby confirming 
in vivo our previous findings in cultured cells 
(Figures 2D, 2E, and 5).
A pre-clinical example of targeted therapy 
guided by a specific mutational signature 
in patient 17
These findings were challenged by integrating the 
study of a freshly resected biopsy from patient 17 (Table I 
and Supplementary Table II) in the working pipeline 
(illustrated in Figure 5A and Supplementary Figure 1). 
First, a fragment of the biopsy was characterized which 
enabled the detection of somatic mutations in the BRAF and 
MAPK7 (ERK5 hereafter) genes (Table I and Figure 5A), 
which were associated with specific inhibitors like 
Vemurafenib (BRAFi (V)) and XMD-8–92 (ERK5i (X)).
Second, freshly isolated melanocytes 
(MELANOMA17 cells hereafter) were also inspected 
for the presence of mutations of BRAF and ERK5 
(Figure 5B) and for the expression of well-known 
melanoma markers such as S100A and MCSP 
(Supplementary Figure 6A and 6B). Once characterized, 
MELANOMA17 cells were incubated with increasing 
concentrations of BRAFi and ERK5i, and the IC50 of 
each was calculated (Supplementary Table III). Treatment 
with BRAFi and ERK5i inhibited B-RAF and ERK5-
dependent signaling, assessed by western blot, in starved 
MELANOMA17 cells (Figure 5C). Simultaneous 
treatment with both inhibitors was more effective at 
reducing MELANOMA17 cell proliferation than either 
inhibitor alone (Figure 5D). Furthermore, and consistent 
with our previous observations in multiple cell lines, the 
combination treatment (BRAFi+ERK5i) was also more 
effective in cells with an appropriate mutational signature 
(MELANOMA17 cells) when compared with a panel of 
other melanoma cell lines (Figure 5E), with the possible 
exception of A375 cells, which were highly sensitive to 
treatment with the BRAFi dose used (compare the IC50 
values for MELANOMA17 with those of A375 cells 
in Supplementary Table III). This combination therapy 
also consisted of MAPK-dependent (BRAFi) and 
MAPK-independent (ERK5i) mechanisms, which 
successfully suppressed the aberrant growth of 
MELANOMA17 cells (Figure 5F).
Third, another fragment of the biopsy was implanted 
in NSG mice and allowed to grow until four tumor-
comparable groups of mice could be established. The 
groups of mice were then treated with vehicle, BRAFi, 
ERK5i, or a combination of the two (V+X). When used 
separately, the two inhibitors were able to suppress 
xenografted MELANOMA17 tumor growth to a similar 
extent, but growth inhibition was more effective when 
used in combination (Figure 5G-5I).
Thus, it is possible to study the effects of 
personalized therapies, guided by targeted mutational 
profiling of advanced melanoma patients, in pre-clinical 
ex vivo and in vivo models using freshly resected material 
from each lesion.
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Figure 2: Effects of specific targeted therapy guided by mutational signature. A. Proliferation analysis of A375 cells at 0, 24 
and 48 h. Cells were seeded in 96-well plates and treated with the indicated concentrations of each inhibitor: B-RAFi (V: Vemurafenib), 
FGFR2i (Va: Vargatef), and mTORi (E: Everolimus). B. Western blots using whole cell lysates from starved A375 cells incubated for 
1 h with control vehicle (DMSO) or the indicated concentration of each inhibitor. The figure shows a representative experiment using 
P-ERK1/2, ERK1/2, P-p38, p38, P-S6 and S6 antibodies, as indicated. C. Proliferation analysis of A375 cells in the same conditions as in 
A), but incubated with control vehicle (DMSO) or the IC50 concentration of the indicated inhibitor alone (blue lines), or in a double (green 
lines) or triple combination (red line). N = 6. Error bars show the SEM. D. DNA synthesis using Click-iT® EdU in exponentially growing 
A375 cells seeded in an 8-well glass and incubated for 48 h with control vehicle (DMSO) or the indicated inhibitor or combination of 
inhibitors, as in C). Graph bars show percentage of low (clear red) or high (intense red) EdU-stained cells in three photographic fields from 
a representative experiment. E. Representative pictures of each treatment condition showing the nucleus of the total number of cells (blue 
dots) and EdU-positive cells (red dots). F and G. Western blots of whole cell lysates of the indicated cells. Cells were starved overnight and 
incubated for 1 h with control vehicle (DMSO), or the indicated inhibitor, or a combination of inhibitors under the same conditions as in 
C). Figures show representative experiments using P-ERK1/2, ERK1/2, P-p38, p38, P-S6 and S6 antibodies, as indicated. Bar graphs show 
the values of three independent experiments in G). Error bars indicate the SEM.
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DISCUSSION
Metastatic melanoma provides an instructive 
example of the development of rationalized therapies 
guided by molecular diagnostics. Mechanistically, 
targeted therapy mainly involves the inhibition of the 
MAPK signaling pathway by using BRAF or MEK 
inhibitors, alone or in combination [21], as suggested by: 
A) activating mutations in BRAF and NRAS oncogenes 
in 48% and 15% of all diagnosed melanomas, respectively 
[22]; and B) multiple MAPK reactivation mechanisms 
that confer resistance to BRAF inhibitors [23–25]. This 
has improved the clinical management of those patients 
with mutated BRAF, whereby targeted inhibition of 
aberrant MAPK signaling can increase their OS by up 
to 11.4 months, although, from a different perspective, it 
still offers a limited benefit to these patients [10, 26, 27]. 
To explain this, we can hypothesize that, as part of 
an intricate network of transforming mechanisms in 
melanoma, this disease simultaneously uses multiple 
oncogenic mechanisms, such as, for example, PI3K, MET 
and GNAQ [28, 29], that, along with MAPK signaling, 
act as mechanistic drivers of the disease and promote 
progression or resistance to therapy. In this regard, data 
from genetically defined melanoma models now show that 
a rational combination of MAPK and PI3K inhibitors can 
improve the effects of therapy when used against specific 
genomic backgrounds [30]. Moreover, patients with 
specific mutations gained greater benefits when treated 
with immunotherapy [31, 32]. Thus, better characterization 
of advanced melanoma lesions could improve our ability 
to treat this disease through the use of specific therapies 
that simultaneously target multiple signaling mechanisms.
From a molecular perspective, melanoma is a very 
heterogeneous disease in which up to 1, 500 somatic 
mutations may be harbored in the coding exons of a single 
lesion [13]. This work studies mutations in 217 genes 
previously shown to be mutated in melanoma [13, 14, 18, 
19, 33, 34] in silico by comparing them with mutations 
in 11 cell lines and 158 human melanomas, and ex vivo 
by characterizing 18 lesions from advanced melanoma 
patients. Under all conditions, genes like BRAF, RAC1, 
FGFR2 and IL6R were mutated at varying frequencies, 
occurring as part of unique mutational signatures 
comprising specific combinations of mutated genes that 
have the potential to participate in multiple signaling 
Figure 3: Increased effects of targeted therapy against an appropriate mutational background. A. Proliferation analysis 
of exponentially growing A375 (BRAF+), SKMEL2 (NRAS+), HT144 (BRAF+), MALME (BRAF+), MEWO and MELANOMA17 
(BRAF+) cells treated with vehicle (DMSO) or the IC50 concentration (calculated for A375 cells) of the indicated inhibitor alone, in a 
double or triple combination for 48 h. N = 6. Error bars show the SEM. B. Western blots of whole cell lysates of the indicated cells. Cells 
were starved overnight and incubated for 1 h with control vehicle (DMSO), or the indicated inhibitor, or a combination of inhibitors under 
the same conditions as in A). Figure shows a representative experiment.
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Figure 4: In vivo effects of a targeted therapy combining MAPK-ERK-dependent and MAPK-ERK-independent 
mechanisms of inhibition. A. Xenografted tumor growth-derived A375 cells injected subcutaneously in 48 BALB/C nude mice. Tumor 
size was monitored until a volume of 100 mm3 was obtained, whereupon mice were assigned to four treatment groups: 1) Control (DMSO, 
blue line); 2) BRAFi (V) (orange line); 3) FGFR2i (Va) + mTORi (E) (green line); and 4) BRAFi (V) + FGFRi (Va) + mTORi (E) (red line). 
Mice were treated daily as indicated (see Materials and Methods for further details) and tumor volumes were measured until day 13, at 
which point the experiment was ended. Data were obtained from the 12 control, 11 (V), 7 (Va+E) and 10 (V+Va+E) mice that survived the 
entire process. Error bars indicate the SEM. B. Representative pictures illustrating the effects of the indicated treatment on the xenografted 
tumors that had been resected or were still in the mice. C. H&E staining of representative tumor sections from five representative mice for 
each treatment condition. Tumor sections were analyzed for Ki67-positive staining D. or by the number of mitoses E. Data are averages 
of five section cuts in each mouse. Error bars indicate the SEM. F. Immunohistochemical (IHC) analysis in tumors corresponding to the 
indicated treatment, as in C), using an anti-phospho ERK antibody stain. G. Tumor sections were analyzed for phosphor-ERK-positive 
staining. Results are the averages of five section cuts per mouse. Error bars indicate the SEM.
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Figure 5: A pre-clinical example of targeted therapy guided by a specific mutational signature in melanoma 
patient 17. A. Schematic representation of the work performed with a freshly resected biopsy from patient 17. B. Sanger sequencing of BRAF 
(above) and MAPK7 (ERK5; below) oncogenes in genomic DNA from control cells or isolated melanocytes from patient 17 (MELANOMA17 
cells). C. Western blots of whole-cell lysates from starved MELANOMA17 cells incubated for 1 h with control vehicle (DMSO) or the indicated 
concentration of each inhibitor BRAFi (V: Vemurafenib) or ERK5i (X: XMD-8–92). The figure shows a representative experiment using 
P-ERK1/2, ERK1/2, ERK5 and tubulin antibodies, as indicated. D. Proliferation analysis of MELANOMA17 cells at 0, 24 and 48 h. 3 × 103 
cells/well were seeded in 96-well plates and treated with control (DMSO) (black line), or an IC50 concentration of B-RAFi (V) (blue line) or 
ERK5i (X) (red line), alone or in combination (green line). N = 6. Error bars show SEM. E. Proliferation analysis of MELANOMA17, A375, 
MEL JUSO, SKMEL2, and MEWO cells at 0, 24 and 48 h, under the same conditions as in D). N = 6. Error bars show the SEM. F. Western 
blots using whole cell lysates of the indicated cells. Cells were starved overnight and incubated for 1 h with control vehicle (DMSO), or the 
indicated inhibitor, or a combination of inhibitors using the same concentrations as in E). Representative experiment using anti-P-ERK1/2 and 
anti-ERK1/2 antibodies. G. Tumor growth derived from 2-mm3 MELANOMA17-derived tumor fragments implanted subcutaneously in 30 
NSG mice (Jackson Laboratories). Tumors were monitored until they attained a volume of 100 mm3, whereupon mice were assigned to four 
comparable treatment groups: 1: Control (DMSO, black line), 2: BRAFi (V) (blue line), 3: ERK5i (X) (red line) and 4: BRAFi (V) + ERK5i (X) 
(green line). Mice were treated daily as indicated (see Materials and Methods for further details) and tumor volumes were monitored until day 13, 
at which point the experiment was ended. Data were obtained from five survivor mice from each treatment group. Error bars indicate the SEM. 
The figure shows a representative image from treated tumors that were still in the mice (above) or had been freshly resected (below). H. Bar 
graph of average changes in tumor volume (left) and mass (right) for each treatment condition. N = 5. Error bars indicate the SEM. I. Examples 
of IHC analysis of tumors corresponding to the treatment indicated in D) using anti-phospho ERK antibody staining. Bar graphs show results for 
tumor sections analyzed for phosphor-ERK-positive staining. Data are the averages of five section cuts per mouse. Error bars indicate the SEM.
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pathways and to be associated with specific inhibitors. 
Functionally, the effects of combination therapies guided 
by specific mutational signatures were analyzed in multiple 
melanoma cells harboring unique mutational signatures. 
Those treatments that simultaneously targeted MAPK-
dependent and MAPK-independent signaling were most 
effective at reducing melanoma growth both ex vivo and 
in vivo. These observations can be aligned with work from 
other laboratories, showing that to promote transformation 
in melanocytes, aberrant MAPK-signaling elicited 
by BRAF or NRAS oncoproteins requires the active 
collaboration of other oncogenes, such as PI3K, RAL-
GDS, GNAS or C-MYC, that can participate in alternative 
signaling pathways [35–38]. Thus, a combination of 
genetically defined inhibitors targeting multiple signaling 
pathways could be more effective against specific cases 
of malignant melanoma. We might expect targeting 
well-known melanoma mechanisms to affect the growth 
of melanoma cells in general, and this can indeed be 
observed in our data. Nevertheless, combination therapies 
guided by specific mutational signatures were most 
effective when used against an appropriate mutational 
background. Furthermore, different BRAF-mutated cell 
lines, each with an individual mutational signature, had 
different sensitivities to BRAF inhibition (Supplementary 
Table III). Finally, our data strongly suggest that 
combining several mutationally selected inhibitors can 
specifically block important mechanisms that participate 
in the control of aberrant melanoma cell growth and in the 
finely tuned cellular decision to activate DNA synthesis 
(Figures 2B, 2C, 2E, 4A, 4D and 4E). This rules out 
the possibility that the results were a consequence of 
nonspecific cytotoxic activities.
Starting with freshly resected material from a 
metastatic lesion (patient 17) and trying to match the timing 
with the clinic, a validated mutational profile was obtained 
within two weeks of resection. This data enabled the study 
of a combination therapy based on inhibitors with MAPK-
dependent (BRAFi) and MAPK-independent (ERK5i) 
mechanisms of action in isolated MELANOMA17 cells 
and in xenografted tumors grown in mice. These gave the 
best results when combinatorial approaches were used. 
Of course, this study provides just one example of what 
targeted characterization of specific lesions might offer 
by way of diagnostic possibilities for human melanoma 
in the near future. Considering its potential applicability 
in routine clinical practice, this approach would require 
several limitations to be overcome. This would entail: 
1) establishing efficient protocols to collect, manipulate 
and characterize specific lesions that are representative 
of the various steps of the disease; 2) managing the 
toxicity due to drug combinations; and 3) dealing with 
tumor heterogeneity and interactions with the immune 
system that may be responsible for the eventual resistance 
acquired after combination treatments. However, there 
is much scope for studying novel strategies for targeted 
therapy following a molecular rationale, particularly in 
a disease like advanced melanoma that offers a limited 
prospect of survival to patients who are suffering from it 
(Supplementary Figure 7).
In summary, by adopting targeted approaches we 
can envisage working with specific signatures of mutated 
genes that can: 1) help characterize individual lesions in 
advanced melanoma patients; 2) guide the use of specific 
inhibitors rationally combined in individualized therapies 
to target case-specific mechanisms of melanocytic 
transformation. In this work, a rational combination of 
genetically defined inhibitors simultaneously targeting 
MAPK-dependent and MAPK-independent signaling 
mechanisms showed improved biological outcomes with 
respect to the malignant growth of specific advanced 
melanomas.
MATERIALS AND METHODS
Cells and reagents for tissue culture
Eight human advanced melanoma cell lines were 
used. A375 (CRL-1619™ ), SK-MEL-28 (HTB-72™), 
SK-MEL-2 (HTB-68™), MALME-3M (HTB-64™), 
MEWO (HTB-65™) and HT-144 (HTB-63™) cells were 
obtained from the American Type Cell Collection (ATCC, 
Rockville, MD). MEL-JUSO (ACC 74) was obtained 
from the German Collection of Microorganisms and Cell 
Cultures (DSMZ, Braunschweig, Germany). Genomic data 
from these cells, including those of the somatic mutations 
detected in this study, are publicly available at the 
Broad-Novartis Cancer Cell Line Encyclopedia website 
(CCLE:http://www.broadinstitute.org). MELANOMA17 
cells were established from a primary biopsy sample, as 
explained in the Supplementary Methods. Commercial 
cell lines were cultured as recommended by ATCC or 
DSMZ and incubated with inhibitors, as described in the 
Supplementary Methods.
Cell proliferation and DNA synthesis assays
Cells growing exponentially to approximately 
50% confluence in T96 well plates were incubated with 
the specific inhibitors while keeping the total amount 
of DMSO (0.5%) constant. Cellular proliferation was 
evaluated using AlamarBlue reagent (Life Technologies) 
and colorimetric changes were quantified using the 
Synergy™ HTX Multi-Mode Microplate Reader (Biotek). 
To assess the effects on DNA synthesis, cells were grown 
in a Millicell EZ SLIDE 8-well glass (Merck Millipore, 
PEZGS0816) and after treatment with specific inhibitors 
were incubated for a further 2 h with Click-iT® EdU 
(Alexa Fluor® 594 Imaging Kit; Life Technologies, 
C10339). Immediately afterwards, cells were prepared for 
microscopy following the manufacturer’s specifications 
(see Supplementary Methods for further explanation). 
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Cell images were captured with a Nikon A1R confocal 
microscope with Plan Apo 10x/0.45NA and Plan ApoVC 
60x/1.40NA objectives.
Genomic DNA samples
Matched tumoral and non-tumoral material was 
obtained from 18 patients diagnosed with advanced 
melanoma and who were being monitored by the Oncology 
Department of the Hospital Universitario Marqués de 
Valdecilla (HUMV; see clinical characteristics in Table I). 
Tumoral DNA samples were obtained from freshly 
frozen tissue samples taken at the time of diagnosis, and 
matched non-tumoral DNA was extracted from saliva or 
peripheral blood neutrophils. We designed an intra-subject 
observational study of patients diagnosed with advanced 
melanoma and with a Breslow index of ≥4 mm, and with 
a loco-regional infiltration in lymph nodes or presenting 
distant metastasis. The study, the patient information 
sheet, and the informed consent form were approved by 
the Ethics Committee of the HUMV.
Enrichment library design, preparation, 
sequencing and variant calling
Genomic DNA samples were processed using the 
Qubit® dsDNA BR Assay Kit (Life Technologies) and 
quantified using Qubit 2.0 apparatus (Life Technologies). 
The DNA enrichment library was prepared using a 
specifically designed HaloPlex Target Enrichment 
System Kit for this melanoma study (Design ID: 00912-
1339502780, Agilent Technologies) following the 
manufacturer’s instructions. The design focused on the 
coding regions of a group 217 genes known to be mutated 
in melanoma, and which were selected because they were: 
A) genes of known relevance in melanoma, including 
BRAF, NRAS [7], and EGFR [18, 19]; B) genes that 
may be associated with pharmacological inhibitors of 
potential clinical use, such as FGFR2, KIT and ERBB4 
[18, 20, 21]; and C) genes that may be involved in 
chromatin architecture (ARID1A and DNMT3A [14]), 
intracellular signaling (MEK1 [22]), or transcription 
(NFATC2 [22]). Briefly, 400 ng of genomic DNA was 
digested with the specific cocktail of restriction enzymes 
provided in the kit. Digested DNA was then hybridized 
to a probe for target enrichment, indexed and captured. 
Each DNA was then amplified by PCR at Tm = 60°C, for 
18 cycles, using a Herculase II Fusion Enzyme kit (Agilent 
Technologies). Next, amplified target libraries were 
purified using an Agencourt AMPure XP Kit (Beckman 
Coulter Genomics), following the manufacturer’s 
guidelines, and quantified with Qubit 2.0 apparatus (Life 
Technologies), using the Qubit® dsDNA HS Assay Kit 
(Life Technologies). They were also analyzed in parallel 
by capillary electrophoresis in a 2100 Bioanalyzer (Agilent 
Technologies), using High Sensitivity DNA reagents and 
chip Kits (Agilent Technologies). Libraries were sequenced 
at the Instituto de Medicina Genómica (IMEGEN, Valencia 
University, Spain) with a MiSeq Personal Sequencer 
(Illumina). The process of somatic mutation identification 
described in the Supplementary Methods.
Somatic mutation identification
Sequencing data were aligned against the human 
reference genome (hg19) using the BWA aligner [39]. The 
alignment was refined using SAMTOOLS fixmate (PMID: 
19505943) and PICARD TOOLS cleanSam tools (http://
broadinstitute.github.io/picard.). Local realignment of 
insertions and deletions (indels) was then performed using 
the GATK suite [40] before final sorting and indexing. 
The RAMSES application (PMID: 24296945), written 
in-house, was used to detect nucleotide substitutions. 
Small indels were identified using Pindel [41] in paired 
tumor-normal mode. For greater specificity, only simple 
insertion and deletion events of fewer than 10 bp were 
selected. An in-house perl script filter was used to extract 
high-quality indels: considering the high sequence 
coverage obtained in these samples, only those indels with 
a minimum coverage of 20 reads in both tumor and normal 
samples, and with a minimum frequency of 10% of the 
reads and a minimum of five independent reads supporting 
the event in the tumor sample, and with no evidence in 
the normal sample, were considered. All potential somatic 
mutations were filtered using the dbSNP132 and 1000 
Genomes Project mutation databases and the functional 
consequence at the protein level was annotated according 
to the Ensembl database using an in-house perl script 
based on the Ensembl database API.
Validation analysis
Genomic DNA was amplified using the specific 
oligonucleotides described in Supplementary Table IV. 
All amplicons from the same patient were mixed in a 
tube and each sample was quantified by Qubit 2.0 (Life 
Technologies), using the Qubit® dsDNA BR Assay 
Kit (Life Technologies). MELANOMA17 cells were 
monitored by Sanger sequencing for the presence of 
mutations in BRAF and MAPK7 (see the supplementary 
methods for further details).
Statistics
Unless otherwise specified, all experiments were 
done in independent triplicates and all numerical data were 
summarized as the average of the values ± the standard 
error of the mean (SEM) using GraphPad PRISM. 
Levels of statistical significance are indicated as follows: 
*p < 0.05; **p < 0.01; ***p < 0.001.
Oncotarget25463www.impactjournals.com/oncotarget
Western blot
Cells growing exponentially at approximately 70% 
confluence were treated under the desired conditions. Cells 
were starved overnight (unless otherwise stated), treated 
with the appropriate inhibitor and lysed as described in 
[42]. Whole cell lysates were subjected to acrylamide 
SDS-PAGE, using standard procedures, then transferred 
onto a nitrocellulose support membrane (Immobilon, 
Millipore) and western blotted. The primary and secondary 
antibodies and the data collection method are described in 
the Supplementary Methods.
Mice and reagents for in vivo studies
BALB/c Nude mice CAnN.Cg-Foxn1nu/Crl 
(Charles River) were injected with 6 × 106 A375 melanoma 
cells in the subcutaneous dorsal area. Approximately one 
week later, the tumor reached a volume of about 100 mm3, 
at which point mice were assigned to four tumor size-
comparable groups of 12 animals and treated as described 
in the Supplementary Methods.
Fresh tissue from patient 17, who had been 
diagnosed with metastatic melanoma (Table I and 
Figure 5), was minced and xeno-injected into NOD.
Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice (commonly known 
as NOD scid gamma (NSG) mice) (Charles River). 
Briefly, the animals were anesthetized using ketamine 
(75 mg/kg) and medetomidine (1.0 mg/kg) and a piece 
of tumor was inserted in the subcutaneous dorsal 
area through a small incision in the skin and allowed 
to grow. Next, mice were sacrificed (as described in 
supplementary methods) and tumors were collected and 
minced into pieces of about 2 mm3 and reimplanted into 
the experimental group of mice. When these mice had 
grown tumors of an approximate volume of 100 mm3, 
they were distributed among four groups of six mice, 
each with comparable tumor volumes and treatments 
were started, as described in Figure 5 and in the 
Supplementary Methods.
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